Northern Trust Corp Denali Therapeutics Inc. Transaction History

Northern Trust Corp

  • $658 Billion
  • Q1 2025

A detailed history of Northern Trust Corp transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,132,173 shares of DNLI stock, worth $16.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,132,173
Previous 1,201,518 5.77%
Holding current value
$16.3 Million
Previous $24.5 Million 37.12%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025
SELL
$13.6 - $23.59 $943,092 - $1.64 Million
-69,345 Reduced 5.77%
1,132,173 $15.4 Million
Q4 2024

Feb 14, 2025
BUY
$20.24 - $31.58 $2.35 Million - $3.66 Million
115,876 Added 10.67%
1,201,518 $24.5 Million
Q3 2024

Nov 13, 2024
BUY
$20.96 - $31.05 $56,235 - $83,307
2,683 Added 0.25%
1,085,642 $31.6 Million
Q2 2024

Aug 14, 2024
SELL
$14.96 - $23.22 $83,087 - $128,963
-5,554 Reduced 0.51%
1,082,959 $25.1 Million
Q1 2024

May 14, 2024
SELL
$15.83 - $23.35 $208,417 - $307,426
-13,166 Reduced 1.2%
1,088,513 $22.3 Million
Q4 2023

Feb 13, 2024
SELL
$16.2 - $23.18 $244,020 - $349,160
-15,063 Reduced 1.35%
1,101,679 $23.6 Million
Q3 2023

Nov 13, 2023
BUY
$20.63 - $30.17 $557,917 - $815,917
27,044 Added 2.48%
1,116,742 $23 Million
Q2 2023

Aug 11, 2023
BUY
$23.37 - $32.96 $1.68 Million - $2.36 Million
71,694 Added 7.04%
1,089,698 $32.2 Million
Q1 2023

May 15, 2023
BUY
$21.91 - $32.67 $740,842 - $1.1 Million
33,813 Added 3.44%
1,018,004 $23.5 Million
Q4 2022

Feb 13, 2023
BUY
$26.28 - $33.92 $2.48 Million - $3.2 Million
94,223 Added 10.59%
984,191 $27.4 Million
Q3 2022

Nov 14, 2022
SELL
$25.97 - $38.53 $16,880 - $25,044
-650 Reduced 0.07%
889,968 $27.3 Million
Q2 2022

Aug 12, 2022
SELL
$20.88 - $35.19 $325,936 - $549,315
-15,610 Reduced 1.72%
890,618 $26.2 Million
Q1 2022

May 13, 2022
SELL
$29.0 - $47.27 $1.53 Million - $2.5 Million
-52,861 Reduced 5.51%
906,228 $29.2 Million
Q4 2021

Feb 08, 2022
BUY
$42.59 - $55.02 $313,632 - $405,167
7,364 Added 0.77%
959,089 $42.8 Million
Q3 2021

Nov 15, 2021
SELL
$48.48 - $78.23 $1.33 Million - $2.14 Million
-27,333 Reduced 2.79%
951,725 $48 Million
Q2 2021

Aug 13, 2021
BUY
$50.3 - $78.44 $11.3 Million - $17.7 Million
225,424 Added 29.91%
979,058 $76.8 Million
Q1 2021

May 12, 2021
SELL
$53.8 - $81.53 $1.3 Million - $1.97 Million
-24,111 Reduced 3.1%
753,634 $43 Million
Q4 2020

Feb 11, 2021
SELL
$36.89 - $93.56 $415,860 - $1.05 Million
-11,273 Reduced 1.43%
777,745 $65.1 Million
Q3 2020

Nov 16, 2020
SELL
$23.13 - $38.84 $1 Million - $1.68 Million
-43,242 Reduced 5.2%
789,018 $28.3 Million
Q2 2020

Aug 14, 2020
BUY
$16.01 - $28.82 $2.15 Million - $3.86 Million
134,061 Added 19.2%
832,260 $20.1 Million
Q1 2020

May 14, 2020
BUY
$14.2 - $27.98 $897,255 - $1.77 Million
63,187 Added 9.95%
698,199 $12.2 Million
Q4 2019

Feb 14, 2020
SELL
$14.4 - $19.99 $279,921 - $388,585
-19,439 Reduced 2.97%
635,012 $11.1 Million
Q3 2019

Nov 13, 2019
BUY
$15.32 - $21.92 $527,023 - $754,069
34,401 Added 5.55%
654,451 $10 Million
Q2 2019

Aug 13, 2019
BUY
$18.5 - $28.14 $112,165 - $170,612
6,063 Added 0.99%
620,050 $12.9 Million
Q1 2019

May 13, 2019
BUY
$17.99 - $24.65 $413 - $566
23 Added 0.0%
613,987 $14.3 Million
Q4 2018

Feb 12, 2019
BUY
$13.88 - $21.75 $195,777 - $306,783
14,105 Added 2.35%
613,964 $12.7 Million
Q3 2018

Nov 14, 2018
BUY
$12.46 - $21.74 $5.15 Million - $8.98 Million
412,925 Added 220.89%
599,859 $13 Million
Q2 2018

Aug 14, 2018
BUY
$15.25 - $21.02 $287,996 - $396,962
18,885 Added 11.24%
186,934 $2.85 Million
Q1 2018

May 09, 2018
BUY
$15.36 - $24.8 $2.58 Million - $4.17 Million
168,049 New
168,049 $3.31 Million

Others Institutions Holding DNLI

# of Institutions
234
Shares Held
127M
Call Options Held
37.3K
Put Options Held
7.9K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $1.93B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email